Telecom software provider Amdocs (NASDAQ: DOX) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 3.9% year on year to $1.17 billion. The company expects next quarter’s revenue to be around $1.18 billion, close to analysts’ estimates. Its non-GAAP profit of $1.78 per share was 0.9% above analysts’ consensus estimates.

Is now the time to buy Amdocs? Find out by accessing our full research report, it’s free.

We are building this strategy on our strong business foundations, as demonstrated by solid Q2 results which show healthy sales, strong customer relationships and consistent operating execution," said Shimie Hortig, president and chief executive officer of Amdocs Management Limited.

Company Overview

Powering the digital experiences of approximately 400 communications companies worldwide, Amdocs (NASDAQ: DOX) provides software and services that help telecommunications and media companies manage customer relationships, monetize services, and automate network operations.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years.

With $4.62 billion in revenue over the past 12 months, Amdocs is one of the larger companies in the business services industry and benefits from a well-known brand that influences purchasing decisions. However, its scale is a double-edged sword because it’s harder to find incremental growth when you’ve penetrated most of the market. For Amdocs to boost its sales, it likely needs to adjust its prices, launch new offerings, or lean into foreign markets.

As you can see below, Amdocs’s 1.9% annualized revenue growth over the last five years was sluggish. This shows it failed to generate demand in any major way and is a rough starting point for our analysis.

Long-term growth is the most important, but within business services, a half-decade historical view may miss new innovations or demand cycles. Amdocs’s performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 3.6% annually.

This quarter, Amdocs reported modest year-on-year revenue growth of 3.9% but beat Wall Street’s estimates by 0.5%. Company management is currently guiding for a 2.7% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 3% over the next 12 months. While this projection implies its newer products and services will spur better top-line performance, it is still below the sector average.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Amdocs has been a well-oiled machine over the last five years. It demonstrated elite profitability for a business services business, boasting an average adjusted operating margin of 18.6%.

Looking at the trend in its profitability, Amdocs’s adjusted operating margin rose by 2.5 percentage points over the last five years, as its sales growth gave it operating leverage.

In Q1, Amdocs generated an adjusted operating margin profit margin of 15.6%, down 5.7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Amdocs’s EPS grew at 9.2% compounded annual growth rate over the last five years, higher than its 1.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

Diving into Amdocs’s quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Amdocs’s adjusted operating margin declined this quarter but expanded by 2.5 percentage points over the last five years. Its share count also shrank by 17.8%, and these factors together are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth.

Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business.

For Amdocs, its two-year annual EPS growth of 8.1% was lower than its five-year trend. We hope its growth can accelerate in the future.

In Q1, Amdocs reported adjusted EPS of $1.78, in line with the same quarter last year. This print was close to analysts’ estimates. Over the next 12 months, Wall Street expects Amdocs’s full-year EPS of $7.14 to grow 8.5%.

Key Takeaways from Amdocs’s Q1 Results

It was good to see Amdocs narrowly top analysts’ revenue expectations this quarter. On the other hand, its full-year EPS guidance missed. Overall, this was a weaker quarter. The stock traded up 1.1% to $60.55 immediately following the results.

So do we think Amdocs is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).